Get the latest news, insights, and market updates on AQST (Aquestive Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Jim Cramer on Aquestive Therapeutics: “I Think It’s a Very Interesting Spec”
Aquestive Therapeutics, Inc. (NASDAQ:AQST) is one of the stocks Jim Cramer recently put under a microscope. When a caller asked about the stock, Cramer stated: “We know the problem. Let’s not look at that. We look at the pipeline and we know that… I’m in favor of investing in a spec of any company involving […] Nov 13, 2025 - $AQST
Looking at the Narrative for Aquestive Therapeutics After Patent Wins and FDA Milestones
Shares of Aquestive Therapeutics have recently attracted attention, as analysts updated their price target assumptions based on new business developments. The changes reflect a mix of optimism around revenue growth and patent extensions for key products. This is balanced by a slightly higher discount rate that captures recent shifts in perceived risk. Stay tuned to discover how you can keep up with future updates and evolving narratives for Aquestive Therapeutics as the story continues to... Nov 9, 2025 - $AQST
Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Nov 5, 2025 - $AQST
Aquestive Therapeutics: Q3 Earnings Snapshot
WARREN, N.J. (AP) — Aquestive Therapeutics Inc. AQST) on Wednesday reported a loss of $15.4 million in its third quarter. The Warren, New Jersey-based company said it had a loss of 14 cents per share. Nov 5, 2025 - $AQST
Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EUAdded clinical leadership to drive long-term successStrengthened balance sheet to support planned commercial launch execution of AnaphylmCompany to host investor call on November 6, 2025, at 8:00am ET WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company adva Nov 5, 2025 - $AQST
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
Changes strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company’s ongoing development initiatives Matthew Davis, M.D., RPh will join immediately as Chief Development OfficerGary Slatko, M.D., M.B.A, will become interim Chief Medical Officer Peter Boyd, M.B.A, has been promoted to Chief People Officer WARREN, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive Nov 4, 2025 - $AQST
Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler
WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that David Amsellem, Sr. Research Analyst at Piper Sandler, will host a live fireside chat with the Company’s management team on November 6, 2025 at 12:00 p.m. ET. The discussion will focus on the Company’s pro Nov 3, 2025 - $AQST
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple